Skip to content

Addiction: all studies

Page 745 of 857: studies 7,441 to 7,450 of 8,563, newest first. Back to the addiction overview

Research

The destruction of the lower urinary tract by ketamine abuse: a new syndrome?

British Journal of Urology August 1, 2008 Peggy Chu, Wai‐kit Ma, Simon Chun‐wing Wong et al. 363 citations

OBJECTIVE: To report the clinical spectrum seen in young abusers of street-ketamine (regular recreational abusers of street-ketamine, for its hallucinogenic effects) in Hong Kong, presenting with significant lower urinary tract symptoms (LUTS) but with no evidence of bacterial infection. PATIENTS AND METHODS: We retrospectively analysed the clinical presentations, pelvic pain and...

Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice

The International Journal of Neuropsychopharmacology July 9, 2008 Thibault Renoir, Eleni Païzanis, Malika El Yacoubi et al. 58 citations

Although numerous studies investigated the mechanisms underlying 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity, little is known about its long-term functional consequences on 5-HT neurotransmission in mice. This led us to evaluate the delayed effects of MDMA exposure on the 5-HT system, using in-vitro and in-vivo approaches in both 5-HTT wild-type and knock-out mice. Acute MDMA...

Spikes, synchrony, and attentive learning by laminar thalamocortical circuits.

Brain Research July 7, 2008 Stephen Grossberg, Massimiliano Versace

This article develops the Synchronous Matching Adaptive Resonance Theory (SMART) neural model to explain how the brain may coordinate multiple levels of thalamocortical and corticocortical processing to rapidly learn, and stably remember, important information about a changing world. The model clarifies how bottom-up and top-down processes work together to realize this goal, notably how...

Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Drug and Alcohol Dependence July 1, 2008 Karen L. Hanson, Mónica Luciana, Kristin Sullwold

The recreational drug, 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'), is a synthetic amphetamine derivative and a serotonin neurotoxin. MDMA use is associated with cognitive dysfunction and impulsivity, but since polydrug abuse is common among users it is difficult to attribute these problems specifically to MDMA. Moreover, few studies have examined reward-related cognitive processes. Our...

Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.

Psychopharmacology July 2008 Lance R Mcmahon, Brett C Ginsburg, R J Lamb

A variety of behavioral procedures have been developed to assess cannabinoid activity in mice; however, the feasibility of establishing Delta(9)-THC as a discriminative stimulus in mice has not been documented. One goal was to establish Delta(9)-THC as a discriminative stimulus in mice; after having done so, another goal was to examine the in vivo mechanism of action of Delta(9)-THC with other...

Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

Toxicology and Applied Pharmacology July 1, 2008 Julien Fonsart, Marie-Claude Menet, Xavier Declèves et al.

The use of the amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) has been associated with unexplained deaths. Male humans and rodents are more sensitive to acute toxicity than are females, including a potentially lethal hyperthermia. MDMA is highly metabolized to five main metabolites, by the enzymes CYP1A2 and CYP2D. The major metabolite in rats,...

Relationship between response rates and measures of reinforcing strength using a choice procedure in monkeys.

Behavioural Pharmacology July 2008 Matthew L Banks, Robert W Gould, Paul W Czoty et al.

Concurrent schedules of reinforcement are increasingly being used to investigate the reinforcing strength of abused drugs. A purported advantage of concurrent schedules is that the primary dependent measure, percentage of responses emitted on the drug-associated manipulandum, is independent of the rate-altering effects of drugs. Data supporting this hypothesis are, however, rarely presented,...

Salvinorin A modulates the neurotransmitters release from different mouse brain areas through presynaptic metabotropic receptors activation

Planta Medica July 1, 2008 Mario Marchi, Massimo Grilli, Elisa Neri et al.

Salvinorin-A is a component of Salvia divinorum , displaying psychoactive and hallucinogenic properties in humans. Recent literature suggests that this compound can act as a potent and selective opioid receptor agonist, having high affinity towards the K–opioid receptor subtype. The aim of our study was to investigate whether and to what extent this compound can alter the release of...

Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol.

European Neuropsychopharmacology July 1, 2008 Simret Beraki, Alexander Kuzmin, Fadao Tai et al.

The effect of phencyclidine (PCP), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, was examined in the water maze, a spatial learning and memory task dependent on hippocampal functions. Male adult C57Bl/6J mice received daily (s.c.) injections of either saline or PCP (0.25-4.0 mg/kg) for 12 days. During the last 5 days, the injections were followed by water maze training....

Human hallucinogen research: guidelines for safety.

Journal of Psychopharmacology July 1, 2008 Mw Johnson, Wa Richards, Rr Griffiths 1,191 citations

There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their...

DOI: 10.1177/0269881108093587 (opens in new tab) Full text (opens in new tab) Hallucinogen research Human research Hallucinogens Clinical trials +21